| Autor: |
Maria Fernanda Imperio Pereira, Isabela Panzeri Carlotti Buzatto, Hélio Humberto Angotti Carrara, Fabiana de Oliveira Buono, Jurandyr Moreira de Andrade, Leonardo Fleury Orlandini, Daniel Guimarães Tiezzi |
| Jazyk: |
English<br />Portuguese |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Revista Brasileira de Ginecologia e Obstetrícia, Vol 46 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
0100-7203 |
| DOI: |
10.61622/rbgo/2024rbgo29 |
| Popis: |
Abstract Objective Neoadjuvant chemotherapy (NACT) has become the standard of care for patients with triple-negative breast cancer (TNBC) with tumors > 1 cm or positive axillary nodes. Pathologic complete response (pCR) has been used as an endpoint to select patients for treatment scaling. This study aimed to examine the benefit of adding adjuvant capecitabine for TNBC patients who did not achieve pCR after standard NACT in a real-world scenario. Methods This retrospective cohort study included all patients with TNBC who underwent NACT between 2010 and 2020. Clinicopathological data were obtained from the patient records. Univariate and multivariate analyses were conducted at the 5 years follow-up period. Results We included 153 patients, more than half of whom had stage III (58.2%) and high-grade tumors (60.8%). The overall pCR rate was 34.6%, and 41% of the patients with residual disease received adjuvant capecitabine. Disease-specific survival (DSS) among the patients who achieved pCR was significantly higher (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
